Plain-English translation of NCT04483206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to stem cell transplantation for multiple myeloma that personalizes the dose of hydrochloride based on how your body processes the medication. Instead of giving everyone the same dose, doctors will measure the medication's level in your blood and adjust the second dose to achieve a target exposure. You'll receive chemotherapy on two days, followed by an infusion of your own stem cells to help rebuild your immune system.
Standard stem cell transplants use a one-size-fits-all chemotherapy dose, but people's bodies process medication differently. This trial is designed to see if tailoring the dose to match how your body handles the medication can make treatment work better and cause fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy () on day -3, then a second personalized dose on day -1 based on blood tests from the first dose. On day 0, you'll receive an infusion of your own previously collected stem cells. You'll stay in close contact with the research team and have follow-up visits at 7, 14, 30, 60, and 90 days after your transplant to monitor your recovery and how well the treatment is working.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States